Jan J. Jobsen

10.5k citations

92 papers · 6.4k indexed · 3 hit papers · h-index 35

Obstetrics and Gynecology top 0.05%
- Endometrial and Cervical Cancer Treatments 45
- Uterine Myomas and Treatments 10
Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment 19
- Endometriosis Research and Treatment 9
Cancer Research top 1%
- Breast Cancer Treatment Studies 31
Pathology and Forensic Medicine top 1%
- Breast Lesions and Carcinomas 16
Oncology top 2%
- Global Cancer Incidence and Screening 11
Epidemiology
- Cervical Cancer and HPV Research 8

Co-authors: Carien L. Creutzberg Ludy Lutgens Carla C. Wárlám-Rodenhuis Marnix L.M. Lybeert Remi A. Nout P. Koper Vincent T.H.B.M. Smit H Beerman
Cited by: Obstetrics and Gynecology Reproductive Medicine Cancer Research
Partner nations: Netherlands United Kingdom France

In The Last Decade

Jan J. Jobsen

91 papers receiving 6.3k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
2015 Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials
2000 Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial

Peers

Countries citing papers authored by Jan J. Jobsen

Since Specialization

Citations

This map shows the geographic impact of Jan J. Jobsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan J. Jobsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan J. Jobsen more than expected).

Fields of papers citing papers by Jan J. Jobsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan J. Jobsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan J. Jobsen. The network helps show where Jan J. Jobsen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jan J. Jobsen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jan J. Jobsen Line = papers co-authored together Jan J. Jobsen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low D. van Dijk,Lisa Vermij,Alicia León‐Castillo,Melanie Powell,Jan J. Jobsen,Alexandra Léary,David Bowes,Linda Mileshkin,Catherine Genestie,Ina M. Jürgenliemk‐Schulz,Cor D. de Kroon,Cathalijne Post,Stephanie M. de Boer,Linda S. Nooij,Judith R. Kroep,Carien L. Creutzberg,Vincent T.H.B.M. Smit,Nanda Horeweg,Tjalling Bosse,Anneke M. Westermann	2024	3
2	Effect of Physical Exercise on MRI‐Assessed Brain Perfusion in Chemotherapy‐Treated Breast Cancer Patients: A Randomized Controlled Trial Emmie W. Koevoets,Jan Petr,Evelyn M. Monninkhof,Mirjam I. Geerlings,Lenja Witlox,Elsken van der Wall,Martijn M. Stuiver,Gabe S. Sonke,Miranda J. Velthuis,Jan J. Jobsen,Job van der Palen,Henk Mutsaerts,Michiel B. de Ruiter,Anne M. May,Sanne B. Schagen,(unknown)	2023	1
3	2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer Nanda Horeweg,Remi A. Nout,Ellen Stelloo,Ludy Lutgens,Jan J. Jobsen,Ina M. Jürgenliemk‐Schulz,Elsbieta M van der Steen-Banasik,Jan-Willem M. Mens,Annerie Slot,Vincent T.H.B.M. Smit,Tjalling Bosse,Carien L. Creutzberg	2022	1
4	2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study Lisa Vermij,Hein Putter,Jan J. Jobsen,Melanie Powell,Stephanie M. de Boer,Alexandra Léary,Paul Bessette,Linda Mileshkin,Ludy Lutgens,Ina M. Jürgenliemk‐Schulz,Annerie Slot,Elzbieta van der Steen-Banasik,Remi A. Nout,Vincent T.H.B.M. Smit,Ewout W. Steyerberg,Carien L. Creutzberg,Tjalling Bosse,Nanda Horeweg	2022	1
5	2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers Lisa Vermij,Jan J. Jobsen,Mariël Brinkhuis,Suzan Roothaan,Alicia León‐Castillo,Naveena Singh,Linda Mileshkin,Melanie Powell,Prafull Ghatage,Meg McLachlin,Alexandra Léary,Catherine Genestie,Hans W. Nijman,Ina M. Jürgenliemk‐Schulz,Remi A. Nout,Vincent T.H.B.M. Smit,Stephanie M. de Boer,Carien L. Creutzberg,Nanda Horeweg,Tjalling Bosse	2022	1
6	2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials Famke C. Wakkerman,Stephanie M. de Boer,Melanie Powell,Alexandra Léary,Anthony Fyles,Linda Mileshkin,Naveena Singh,Remi A. Nout,Ina M. Jürgenliemk‐Schulz,Jan J. Jobsen,Ludy Lutgens,Elsbieta M van der Steen-Banasik,Jan-Willem M. Mens,Annerie Slot,Hans W. Nijman,Vincent T.H.B.M. Smit,Tjalling Bosse,Carien L. Creutzberg,Nanda Horeweg	2022	1
7	Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer Elke E.M. Peters,Alicia León‐Castillo,Vincent T.H.B.M. Smit,Marie Boennelycke,Estrid Høgdall,Claus Høgdall,Carien L. Creutzberg,Ina M. Jürgenliemk‐Schulz,Jan J. Jobsen,Jan Willem Mens,Ludy Lutgens,Elzbieta M. van der Steen‐Banasik,Gitte Ørtoft,Tjalling Bosse,Remi A. Nout	2021	47
8	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer Nanda Horeweg,Marco de Bruyn,Remi A. Nout,Ellen Stelloo,Katarzyna Kedzierska,Alicia León‐Castillo,Annechien Plat,Kirsten D. Mertz,Michelle Osse,Ina M. Jürgenliemk‐Schulz,Ludy Lutgens,Jan J. Jobsen,Elzbieta M. van der Steen‐Banasik,Vincent T.H.B.M. Smit,Carien L. Creutzberg,Tjalling Bosse,Hans W. Nijman,Viktor H. Koelzer,David N. Church	2020	42
9	An actualised population‐based study on the use of radiotherapy in breast cancer patients in the Netherlands K. Schreuder,Judith G. Middelburg,Mieke J. Aarts,J. W. S. Merkus,Philip Poortmans,Jan J. Jobsen,Sabine Siesling,H. Struikmans	2019	10
10	Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): protocol of a randomised controlled trial Lenja Witlox,Sanne B. Schagen,Michiel B. de Ruiter,Mirjam I. Geerlings,Petra H.M. Peeters,Emmie W. Koevoets,Elsken van der Wall,Martijn M. Stuiver,Gabe S. Sonke,Miranda J. Velthuis,Job van der Palen,Jan J. Jobsen,Anne M. May,Evelyn M. Monninkhof	2019	21
11	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy (unknown),Bastiaan G. Wortman,Carien L. Creutzberg,Hein Putter,I.M. Jürgenliemk-Schulz,Jan J. Jobsen,Ludy Lutgens,Elzbieta M. van der Steen‐Banasik,Jan Willem Mens,Annerie Slot,Marika C. Stenfert Kroese,Baukelien van Triest,Hans W. Nijman,Ellen Stelloo,Tjalling Bosse,Stephanie M. de Boer,Wim L.J. van Putten,Vincent T.H.B.M. Smit,Remi A. Nout	2018	163
12	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohortsbreakdown → Ellen Stelloo,Remi A. Nout,Elisabeth M. Osse,Ina J. Jürgenliemk-Schulz,Jan J. Jobsen,Ludy Lutgens,Elzbieta M. van der Steen‐Banasik,Hans W. Nijman,Hein Putter,Tjalling Bosse,Carien L. Creutzberg,Vincent T.H.B.M. Smit	2016	569
13	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women Marjanka K. Schmidt,Alexandra J. van den Broek,Rob A.�E.�M. Tollenaar,Vincent T.H.B.M. Smit,Pieter J. Westenend,Mariël Brinkhuis,Wolter Oosterhuis,Jelle Wesseling,Maryska L.G. Janssen‐Heijnen,Jan J. Jobsen,Agnes Jager,Adri C. Voogd,Flora E. van Leeuwen,Laura van ‘t Veer	2016	51
14	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial Stephanie M. de Boer,Remi A. Nout,Ina M. Jürgenliemk‐Schulz,Jan J. Jobsen,Ludy Lutgens,Elzbieta M. van der Steen‐Banasik,Jan Willem Mens,Annerie Slot,Marika C. Stenfert Kroese,Simone Oerlemans,Hein Putter,Karen Verhoeven-Adema,Hans W. Nijman,Carien L. Creutzberg	2015	85
15	Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy Jan J. Jobsen,Job van der Palen,Michael Baum,Mariël Brinkhuis,H. Struikmans	2013	18
16	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data Remi A. Nout,Hein Putter,Ina M. Jürgenliemk‐Schulz,Jan J. Jobsen,Ludy Lutgens,Elzbieta M. van der Steen‐Banasik,Jan Willem Mens,Annerie Slot,Marika C. Stenfert Kroese,Hans W. Nijman,Lonneke V. van de Poll‐Franse,Carien L. Creutzberg	2011	114
17	Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma Carien L. Creutzberg,Remi A. Nout,Marnix L.M. Lybeert,Carla C. Wárlám-Rodenhuis,Jan J. Jobsen,Jan-Willem M. Mens,Ludy Lutgens,Elisabeth Pras,Lonneke V. van de Poll‐Franse,Wim L.J. van Putten	2011	227
18	Long-Term Improvement in Treatment Outcome After Radiotherapy and Hyperthermia in Locoregionally Advanced Cervix Cancer: An Update of the Dutch Deep Hyperthermia Trial Martine Franckena,Lukas J.A. Stalpers,P. Koper,Ruud Wiggenraad,Wim J. Hoogenraad,J.D.P. van Dijk,Carla C. Wárlám-Rodenhuis,Jan J. Jobsen,Gerard C. van Rhoon,Jacoba van der Zee	2007	149
19	Explanatory factors for variation in the use of breast conserving surgery and radiotherapy in the Netherlands, 1990–2001 Sabine Siesling,Lonneke V. van de Poll‐Franse,Jan J. Jobsen,O.J. Repelaer van Driel,Adri C. Voogd	2007	22
20	Family history in breast cancer is not a prognostic factor? Jan J. Jobsen,J.H. Meerwaldt,Job van der Palen	2000	13

About Jan J. Jobsen

Jan J. Jobsen is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Cancer Research, having authored 92 papers that have together received 6.4k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (45 papers), Breast Cancer Treatment Studies (31 papers), Ovarian cancer diagnosis and treatment (19 papers), Breast Lesions and Carcinomas (16 papers), Global Cancer Incidence and Screening (11 papers), Uterine Myomas and Treatments (10 papers), Endometriosis Research and Treatment (9 papers) and Cervical Cancer and HPV Research (8 papers). The work is most often cited by research in Obstetrics and Gynecology (4.3k citations), Reproductive Medicine (3.1k citations) and Cancer Research (1.4k citations). Jan J. Jobsen has collaborated with scholars based in Netherlands, United Kingdom and France. Frequent co-authors include Carien L. Creutzberg, Ludy Lutgens, Carla C. Wárlám-Rodenhuis, Marnix L.M. Lybeert, Remi A. Nout, P. Koper, Vincent T.H.B.M. Smit, H Beerman, M. van Lent and Elzbieta M. van der Steen‐Banasik.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact